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Background: Early recognition of infectious processes in neutropenic patients is hampered by
the  fact that these processes may have dissimilar and non-speciﬁc clinical presentations.
CD64 is a neutrophil surface marker that is not expressed in non-sensitized neutrophils.
When the neutrophil is exposed to tumor necrosis factor-alpha it is activated and is mea-
sured via the CD64 index.
Methods: This paper evaluated the relationship between the index value of CD64 on the
ﬁrst  day of febrile neutropenia and a positive blood culture. The correlations with white
blood count, C-reactive protein and erythrocyte sedimentation rate were also evaluated.
This  case–control, prospective, diagnostic study included 64 episodes of neutropenia. Case
group  (n = 14) comprised positive blood cultures, and the control group (n = 50), negative blood
cultures.
Results: The median rates of CD64 were 2.1 ( ± 3.9) in the case group and 1.76 ( ± 5.02) in
the  control group. There was no correlation between the value of the CD64 index and blood
cultures. The CD64 index was also not correlated with C-reactive protein positivity. Further-
more, the CD64 index was not able to predict blood culture positivity. The sensitivity was
64.3%, the speciﬁcity was 42%, the positive predictive value was 23.7% and the negative pre-
dictive value was 80%. For C-reactive protein, the sensitivity, speciﬁcity, positive predictive
value, and negative predictive value were 71.4%, 32%, 22.7%, and 80%, respectively.
Conclusion: The CD64 index is not suitable for predicting the positivity of blood cultures in
this  speciﬁc population of patients with febrile neutropenia.©  2015 Associac¸ão Bra
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was deﬁned as death or admission into the ICU because of
sepsis.396  rev bras hematol hem
Introduction
The treatment of childhood cancer is one of the major suc-
cess stories of healthcare at the end of the 20th century.1
Nevertheless, one in every 25 children with cancer dies from
the complications of treatment, corresponding to one in every
six deaths.2,3 Infection frequently manifests as fever and neu-
tropenia, which is known as ‘febrile neutropenia’.4
Some studies have shown that the incidence of septic shock
among children with febrile neutropenia and positive cul-
tures is approximately 19% and that cultures are positive in
83% of the patients requiring intensive care.5–7 Early diag-
nosis of infection allows the immediate onset of antibiotic
treatment, with consequent improvement of survival in this
patient population.8
According to available evidence, the white cell count is a
poor test for distinguishing the infection type in patients with
neutropenia. Nevertheless, some studies have reported that
an absolute neutrophil count less than 0.1 × 109/L is an inde-
pendent predictor of sepsis in severe neutropenic patients.9
C-reactive protein (CRP) and procalcitonin are produced as
a part of the inﬂammatory response. Both proteins are widely
used in the clinical practice in the diagnosis and management
of patients with sepsis. Because CRP levels increase in the
acute phase of inﬂammation, this protein is widely used to
detect active infectious-inﬂammatory processes, particularly
in the pediatric setting.10
The results of CRP testing are controversial, and the sensi-
tivity and speciﬁcity of the assay are limited.11–13 Detection of
this protein seems to be more  useful at the onset of inﬂam-
mation, particularly within the ﬁrst 24 h, as its sensitivity is
higher at this stage compared to that in the late stages of
sepsis.14
CD64 is a membrane glycoprotein that mediates endocy-
tosis, phagocytosis, antibody-dependent cellular cytotoxicity,
cytokine release, and superoxide production. It is normally
expressed on the surfaces of monocytes and macrophages.15
In non-stimulated neutrophils, surface CD64 is expressed
in very low amounts. However, its expression increases in
infections and/or sepsis as a result of neutrophil stimulation
by inﬂammatory cytokines.16,17 The increase in CD64 expres-
sion is proportional to the cytokine stimulus and remains
stable for approximately 24 h.7
A recent study reported that the antigens expressed on
leukocyte surfaces might be used as markers of sepsis in
patients admitted to adult and neonatal intensive care units
(ICUs), as their sensitivity and speciﬁcity are satisfactory.18–20
Technological advances in ﬂow cytometry have allowed the
rapid and precise quantiﬁcation of CD64 expression with a
minimal amount of blood (i.e., approximately 0.5 mL).
In adults, one study showed that a CD64 index value
<1.19 was predictive of negative blood cultures, while a CD64
index value >1.9 was predictive of positive cultures with 94.6%
sensitivity and 88.7% speciﬁcity and positive and negative pre-
dictive values of 89.8% and 94%, respectively.20
The study of early markers of sepsis, such as CD64 is rel-
evant because it allows the earliest possible establishment
of treatment and an adjustment of the duration of antibiotic
treatment.21 2 0 1 5;3  7(6):395–399
CD64 expression has been little investigated in neutropenic
patients. The authors were not able to locate any reference in
the literature as to the use of CD64 as a marker in patients with
neutropenia, certainly not as concerns children with febrile
neutropenia.
The aim of this study was to establish whether CD64
expression in neutrophils, which is a sensitive, rapid and easy-
to-measure index, might be useful in children with febrile
neutropenia. In addition, this study analyzed the patients’
hematological proﬁles to investigate the behavior of CRP levels
relative to the blood culture results.
Methods
A prospective, diagnostic, case–control study was performed
of under 18-year-old children admitted to the Pediatric Hema-
tology Services of the Hospital de Clínicas de Porto Alegre
(HCPA) and Hospital da Crianc¸a  Santo Antônio (HCSA) from
May 2011 to June 2014.
Seventy-one episodes of febrile neutropenia in patients
undergoing chemotherapy were selected independently from
the type of underlying oncological–hematological diseases
that required antibiotic treatment during the study period
with 63 episodes being eligible for inclusion in this study. All
the patients and/or their guardians signed informed consent
forms and the study was approved by the institutions’ Ethics
Committee (# 100559).
Suspected infection was deﬁned as one episode of fever
>38.3 ◦C or two episodes of fever of 38.0 ◦C within 24 h in neu-
tropenic patients subjected to empirical antibiotic treatment
for sepsis. The group of cases included patients with con-
ﬁrmed diagnosis of sepsis, which was deﬁned as positive blood
culture results.
The group of patients without sepsis included children
with suspected infection but negative blood culture results.
Single episodes of febrile neutropenia were considered; thus,
the same patient may have been included more  than once.
Two blood samples for cultures (one from a peripheral vein
and one from a catheter) were obtained at arrival in the
Emergency Room or during hospitalization at the time of
the diagnosis of febrile neutropenia. In addition to CD64
expression and blood cultures, the white cell count, erythro-
cyte sedimentation rate (ESR) and CRP were assessed. The
under 18-year-old patients were included in this study if they
had neutropenia (absolute neutrophil count <0.5 × 109/L or
0.5–1.0 × 109/L that decreased to <0.5 × 109/L during an episode
of fever in patients undergoing chemotherapy) associated with
one episode of fever >38.3 ◦C or two episodes of fever of
38.0 ◦C within 24 h. Patients undergoing chemotherapy and
with fever but with absolute neutrophil counts >1.0 × 109/L,
those with blood cultures positive for fungi, and those who
refused to participate in the study were not included. The sam-
ples were also compared regarding outcome. A poor outcomePeripheral blood samples (0.5 mL)  were collected follow-
ing the ﬁrst episode of fever at the time of culture sample
collection. The CD64 expression was measured by means
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or negative (<1.19).20 The following are the test efﬁcacy meas-
ures: sensitivity 64.3%, speciﬁcity 42%, positive predictive
value 23.7% and negative predictive value 80% (Table 2).
Table 1 – Distribution of the population by age, gender
and blood culture results.
Average age (years) 7.6 ± 5.1
Gender – n (%)
Male 28 (43.8)rev bras hematol hemot
f quantitative ﬂow cytometry using a FACSCalibur device
Becton Dickinson, NY, USA) and a Leuko64 kit (Trillium Diag-
ostics, LLC, ME,  USA).
Descriptive data, such as age and gender, were summa-
ized as means and simple frequencies. A receiver operating
haracteristic (ROC) curve was used to analyze the potential
apacity of the CD64 index to predict positive blood culture
esults. Correlation of the CD64 index with the white cell
ount, ERS and CRP and outcome was assessed using the
ann–Whitney test. All the analyses were performed using
he Statistical Package for the Social Sciences (SPSS) version
2.0 (IBM Corp., Armonk, NY). The signiﬁcance level was set at
 p-value <0.05.
The sample size was calculated based on data available
n the literature.20 In order to detect a two-fold increase
n CD64 levels, a 90% power and a signiﬁcance level of
.05 were considered. The cut-off levels of CD64 index were
.19 in the negative culture group and 2.38 in the posi-
ive culture group. Thus, 40 episodes of neutropenia were
equired (32 negative cultures and eight positive cultures). The
indows version of the PEPI suite of programs for epidemiol-
gists, WINPEPI (version 3.2.2) was used to determine sample
ize.22
ample  preparation  and  CD64  quantiﬁcation
he neutrophil population was analyzed in a FACSCalibur®
ow cytometer (BD Biosciences, San Jose, CA, USA) using
 Leuko64TM kit (Trillium Diagnostics, Brewer, ME, USA),
hich performs quantitative immunotyping by ﬂow cytom-
try based on an antigen–antibody (Ag–Ab) reaction with
uorescent beads. The kit consists of three monoclonal
ntibodies, two speciﬁc to CD64 (both conjugated with ﬂu-
rescein isothiocyanate – FITC) and one speciﬁc for CD163
clone Mac2-158, conjugated with phycoerythrin – PE), a con-
entrated lysing reagent, and ﬂuorescent suspension beads,
hich are used to calibrate and standardize the device
or CD64 and CD163 expression in human blood leuko-
ytes.
The samples were prepared following the kit manu-
acturer’s instructions. To improve the test quality and
oncentrate the cells, leukocyte concentration (Buffy coat) was
erformed.23
The samples were prepared as follows: 50 L of blood (after
eing submitted to leukocyte concentration – Buffy coat) was
ncubated at room temperature in the dark for 15 min  with
0 L of reagent A (the mixture of the monoclonal anti-CD64
ITC antibodies and the monoclonal anti-CD163 PE antibody).
ext, 1.0 mL  of Trillium Lyse solution was added, followed by
ncubation at room temperature in a dark chamber for 15 min.
hen, 5.0 L of reagent C (Leuko64® beads) was added, and
00,000 events were acquired within 24 h via ﬂow cytome-
ry.
Lymphocytes were used as the internal negative control
CD64 < 1.0) and monocytes as the internal positive control
CD64 > 1.0). The sample results (polymorphonuclear neu-
rophils – CD64 PMNs) were considered reliable only when
he values corresponding to the internal positive and negative
ontrols were within the expected ranges. 1 5;3  7(6):395–399 397
Results
Seventy-one episodes of neutropenia were analyzed. Four
were excluded because the blood cultures tested positive for
fungi and three because they were not analyzed within the
established time limit. Therefore, 64 events met  the inclusion
criteria and were eligible for this study.
The average age of the participants was 7.6 years old
(standard deviation: 5.1 years). The distribution of the sample
per gender was balanced: 28 episodes (43.8%) occurred in boys
and 36 (56.3%) in girls (Table 1). Thirteen of the 64 analyzed
episodes corresponded to children with two or more  episodes
of neutropenia; they were considered as separate events and
were included as such in the analysis. Among the 64 included
events, 14 episodes had positive blood culture results, and 50
had negative results.
The median CD64 index value in the positive culture group
was 2.71 (interquartile range: 1.87) and the median CD64 index
value in the negative culture group was 1.76 (interquartile
range: 2.9).
Regarding the underlying neoplastic diseases of the
patients with neutropenia, 45 episodes corresponded to chil-
dren with hematological neoplasms and 19 to children with
solid tumors. In the group with hematological diseases, nine
episodes were associated with positive blood cultures and 36
with negative cultures and in the group with solid tumors,
the blood cultures were positive in ﬁve patients and negative
in 14 patients. The mean neutrophil count was 1.73 × 109/L
( ± 1.80 × 109/L) and the mean total leukocyte count was
2.46 × 109/L ( ± 5.79 × 109/L).
Regarding the blood cultures, coagulase-negative Staphylo-
coccus was isolated in three episodes (all patients had clinical
signs of infection), Escherichia coli in two, Pseudomonas aeru-
ginosa in two, Klebsiella pneumoniae in two, Enterobacter cloacae
in one, Haemophilus sp. in one, Streptococcus dysgalactiae in
one, Streptococcus hominis in one and Ralstonia mannitolilytica in
one.
Analysis of the ROC curve revealed that the CD64 index
crossed the negative and the positive ﬁelds at least once, indi-
cating that the curve was not able to predict the blood culture
results [area under the curve (AUC): 0.491]. This also happened
with the CRP (AUC: 0.529), leukocyte count (AUC: 0.535) and
neutrophil count (AUC: 0.548).
The CD64 index was categorized as either positive (>1.19)Female 36 (56.3)
Blood culture – n (%)
Positive 14 (21.0)
Negative 50 (79.0)
398  rev bras hematol hemoter.
Table 2 – CD64 index values and C-reactive protein (CRP)
efﬁcacy measures.
CD64 index value (%) CRP (%)
Sensitivity 64.3 71.4
Speciﬁcity 42.0 32.0
r
Treatment of Cancer (EORTC). Br J Haematol. 1997;99(3):580–8.Positive predictive value 23.7 22.7
Negative predictive value 80.8 80.0
Based on the laboratory reference values, CRP was catego-
rized as positive (>4 mg/L) or negative (<4 mg/L). The following
are the test efﬁcacy measures: sensitivity 71.4%, speciﬁcity
32%, positive predictive value 22.7% and negative predictive
value 80% (Table 2).
The signiﬁcance (p-value) of the two-tailed test assessing
the correlation between CD64 expression and blood culture
results, categorized CRP, ESR, and outcome were 0.20, 0.53,
0.15, and 0.49, respectively. These results indicate a lack of
correlation between CD64 expression and the variables. The
result of the two-tailed test to assess the correlation between
outcome and categorized CRP was 0.06. Regarding the corre-
lation between blood culture results and CRP, a statistically
signiﬁcant difference was not found between the groups.
Discussion
Febrile neutropenia is a risk factor for septic shock; it is usually
associated with few patent clinical manifestations at its onset.
Thus, all efforts to identify positive blood culture results as
early as possible are of extreme importance. Upon exposure to
pathogens, neutrophils are activated; the identiﬁcation of this
state by optical microscopy occurs only at later stages through
the visualization of toxic granulation.
Analysis of surface marker expression by means of ﬂow
cytometry allows earlier detection of the state of neutrophil
activation.24 In recent years, the neutrophil surface receptor
CD64 has been the focus of several studies on biomarkers.
In one study that assessed a small number of adults with
severe sepsis, the sensitivity of increased CD64 index val-
ues was similar to that of procalcitonin, but less speciﬁc.25 A
recently published prospective study assessed CD64 expres-
sion in a neonatal ICU; the study included 700 patients and
performed more  than 1000 assessments of sepsis. The results
indicated low prevalence of sepsis (5%), and most cases were of
late sepsis. Increased CD64 expression in neonates exhibited
75% sensitivity and 77% speciﬁcity.26
In another study, the ROC AUC demonstrated the capacity
of the CD64 index to predict positive culture results with 91.7%
sensitivity and 88.9% speciﬁcity.27
In the present study, the usefulness of CD64 expression was
assessed as a predictor of positive blood culture results. This
study also assessed the association of the CD64 index with
positive blood culture results, CRP and ESR.
The median CD64 index values were similar in both groups.
It was not possible to detect any relationship between the
CD64 index value and positive blood culture results or with
positive CRP results.
The efﬁcacy measures of the CD64 index (64.3% sensitivity
and 42% speciﬁcity) were lower than those described in the 2 0 1 5;3  7(6):395–399
literature.26 These results disagree with the data reported in
the literature20 for patients without neutropenia.
There are no data in the literature as to CD64 expression in
neutropenic populations. The CD64 index was not adequate
to assess infection in the population with febrile neutropenia
analyzed in the present study.
In this study, no relationship between the CD64 index value
and positive blood culture results was detected. Moreover, the
CD64 index did not exhibit a correlation with positive CRP
results. Therefore, this study does not support data published
for patients without neutropenia; the CD64 index was not able
to predict positive blood culture results in this speciﬁc popu-
lation of patients with febrile neutropenia.
The CRP values did not exhibit any statistically signiﬁcant
differences between the groups with or without positive blood
culture results. This ﬁnding indicates that the elevation of
CRP alone is not indicative of positive blood culture results in
patients with neutropenia. This result agrees with previously
published data.11
However, the result of the two-tailed test to assess the cor-
relation between poor outcome and categorized CRP was 0.06.
Although not statistically signiﬁcant, this value indicates a
strong trend toward signiﬁcance.
Thus, further studies are needed to establish whether there
is a relationship between positive CPR and a poor outcome
and the efﬁcacy of CD64 expression to predict positive blood
culture results in patients with febrile neutropenia. Further-
more,  it is important to assess the usefulness of CD64 as a test
capable of identifying a high-risk group among patients with
febrile neutropenia, in order to achieve an early diagnosis and
to manage these patients.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. Moscucci O, Herring R, Berridge V. Networking health
research in Britain: the post-war childhood leukaemia trials.
20  Century Br Hist. 2009;20(1):23–52.
2. Freycon F, Trombert-Paviot B, Casagranda L, Bertrand Y,
Plantaz D, Marec-Bérard P. Trends in treatment-related deaths
(TRDs) in childhood cancer and leukemia over time: a
follow-up of patients included in the childhood cancer
registry of the Rhône-Alpes region in France (ARCERRA).
Pediatr Blood Cancer. 2008;50(6):1213–20.
3. Hargrave DR, Hann II, Richards SM, Hill FG, Lilleyman JS,
Kinsey S, et al. Progressive reduction in treatment-related
deaths in Medical Research Council childhood lymphoblastic
leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J
Haematol. 2001;112(2):293–9.
4. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A
comparison of outcome from febrile neutropenic episodes in
children compared with adults: results from four EORTC
studies. International Antimicrobial Therapy Cooperative
Group (IATCG) of the European Organization for Research and5. Egyed M, Kollár B, Karádi E, Rajnics P, Kocsondi L, Rumi G.
Neutropenia and sepsis in hematologic patients. Orv Hetil.
2006;147(42):2031–3.
er. 2 0
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
27. Soni S, Wadhwa N, Kumar R, Faridi MM,  Sharma S, Chopra A,
et  al. Evaluation of CD64 expression on neutrophils as an
early indicator of neonatal sepsis. Pediatr Infect Dis J.rev bras hematol hemot
6. Scheinemann K, Ethier MC, Dupuis LL, Richardson SE, Doyle J,
Allen U, et al. Utility of peripheral blood cultures in
bacteremic pediatric cancer patients with a central line.
Support Care Cancer. 2010;18(8):913–9.
7. Hoffmeyer F, Witte K, Schmidt RE. The high-afﬁnity Fc
gamma RI on PMN: regulation of expression and signal
transduction. Immunology. 1997;92(4):544–52.
8. Phillips B, Selwood K, Lane SM, Skinner R, Gibson F, Chisholm
JC.  Variation in policies for the management of febrile
neutropenia in United Kingdom Children’s Cancer Study
Group centres. Arch Dis Child. 2007;92(6):495–8.
9. Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J,
et  al. Risk prediction in pediatric cancer patients with fever
and neutropenia. Pediatr Infect Dis J. 2010;29(1):53–9.
0. Jaye DL, Waites KB. Clinical applications of C-reactive protein
in  pediatrics. Pediatr Infect Dis J. 1997;16(8):735–46, quiz 746–7.
1. Kassam A, Chan AK, Dzolganovski B, Constantin J, Ramphal
R,  Grant R, et al. No association between protein C levels and
bacteremia in children with febrile neutropenia. J Pediatr
Hematol Oncol. 2009;31(9):647–50.
2. Avabratha KS, Rau AT, Venkataravanamma P, Rau A.
Signiﬁcance of C-reactive protein during febrile neutropenia
in pediatric malignancies. Indian Pediatr. 2009;46(9):797–9.
3. Spasova MI, Grudeva-Popova JG, Kostyanev SS, Genev ED,
Stoyanova AA, Kirina VI, et al. Risk index score for bacteremia
in  febrile neutropenic episodes in children with
malignancies. J BUON. 2009;14(3):411–8.
4. Hofer N, Zacharias E, Müller W,  Resch B. An update on the use
of C-reactive protein in early-onset neonatal sepsis: current
insights and new tasks. Neonatology. 2012;102(1):25–36.
5. Davis BH. Improved diagnostic approaches to infection/sepsis
detection. Expert Rev Mol Diagn. 2005;5(2):193–207.
6. Quayle JA, Watson F, Bucknall RC, Edwards SW. Neutrophils
from the synovial ﬂuid of patients with rheumatoid arthritis
express the high afﬁnity immunoglobulin G receptor, Fc
gamma RI (CD64): role of immune complexes and cytokines
in induction of receptor expression. Immunology.
1997;91(2):266–73.
7. Hallett MB, Lloyds D. Neutrophil priming: the cellular signals
that say ‘amber’ but not ‘green’. Immunol Today.
1995;16(6):264–8. 1 5;3  7(6):395–399 399
8. Zeitoun AA, Gad SS, Attia FM, Abu Maziad AS, Bell EF.
Evaluation of neutrophilic CD64, interleukin 10 and
procalcitonin as diagnostic markers of early- and late-onset
neonatal sepsis. Scand J Infect Dis. 2010;42(4):299–305.
9. Groselj-Grenc M, Ihan A, Pavcnik-Arnol M, Kopitar AN,
Gmeiner-Stopar T, Derganc M. Neutrophil and monocyte CD64
indexes, lipopolysaccharide-binding protein, procalcitonin
and C-reactive protein in sepsis of critically ill neonates and
children. Intensive Care Med. 2009;35(11):1950–8.
0. Icardi M, Erickson Y, Kilborn S, Stewart B, Grief B, Scharnweber
G. CD64 index provides simple and predictive testing for
detection and monitoring of sepsis and bacterial infection in
hospital patients. J Clin Microbiol. 2009;47(12):3914–9.
1. Schüttrumpf S, Binder L, Hagemann T, Berkovic D, Trümper L,
Binder C. Procalcitonin: a useful discriminator between
febrile conditions of different origin in hemato-oncological
patients? Ann Hematol. 2003;82(2):98–103.
2. Abramson J. WINPEPI (PEPI-for-Windows). Available at:
http://www.brixtonhealth.com/pepi4windows.html
3. Santos AP, Bandeira MB, Siqueira L. Comparac¸ão entre
diversos métodos de contagem diferencial de leucócitos em
pacientes leucopênicos. Rev Bras Hematol Hemoter.
2009;31(3):203–5.
4. Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou
C, Augustatou K, et al. Neutrophil CD64 expression and
serum IL-8: sensitive early markers of severity and outcome
in  sepsis. Cytokine. 2006;36(5–6):283–90.
5. Cardelli P, Ferraironi M, Amodeo R, Tabacco F, De Blasi RA,
Nicoletti M, et al. Evaluation of neutrophil CD64 expression
and procalcitonin as useful markers in early diagnosis of
sepsis. Int J Immunopathol Pharmacol. 2008;21(1):43–9.
6. Streimish I, Bizzarro M, Northrup V, Wang C, Renna S, Koval
N, et al. Neutrophil CD64 as a diagnostic marker in neonatal
sepsis. Pediatr Infect Dis J. 2012;31(7):777–81.2013;32(1):e33–7.
